Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- 3 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 16 (11), 1600-1603
- https://doi.org/10.1634/theoncologist.2011-0229
Abstract
Background.: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients. Methods.: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998–2002 to 2003–2007. Results.: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998–2002 to 40.3% and 20.8%, respectively, in 2003–2007. The greatest improvements were observed for patients aged 15–44 years, with 5- and 10-year RSRs reaching >70% and ∼50%, respectively, but improvements were also seen for patients aged >70 years. Conclusion.: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.Keywords
This publication has 16 references indexed in Scilit:
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 StudyJournal of Clinical Oncology, 2010
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 TrialJournal of Clinical Oncology, 2009
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2009
- Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010Haematologica, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Up-to-date and Precise Estimates of Cancer Patient Survival: Model-based Period AnalysisAmerican Journal of Epidemiology, 2006
- United States life tables, 2000.2002
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978